Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
PLoS One ; 17(9): e0273854, 2022.
Article in English | MEDLINE | ID: mdl-36048805

ABSTRACT

BACKGROUND: There is no clear evidence whether pirfenidone has a benefit in patients with probable or possible UIP, i.e. when idiopathic pulmonary fibrosis (IPF) is diagnosed with a lower degree of diagnostic certainty. We report on outcomes of treatment with pirfenidone in IPF patients diagnosed with various degrees of certainty. METHODS AND FINDINGS: We followed patients in the multi-national European MultiPartner IPF Registry (EMPIRE) first seen between 2015 and 2018. Patients were assessed with HRCT, histopathology and received a multi-disciplinary team (MDT) IPF diagnosis. Endpoints of interest were overall survival (OS), progression-free survival (PFS) and lung function decline. RESULTS: A total of 1626 patients were analysed, treated with either pirfenidone (N = 808) or receiving no antifibrotic treatment (N = 818). When patients treated with pirfenidone were compared to patients not receiving antifibrotic treatment, OS (one-, two- and three-year probability of survival 0.871 vs 0.798; 0.728 vs 0.632; 0.579 vs 0.556, P = 0.002), and PFS (one-, two- and three-year probability of survival 0.597 vs 0.536; 0.309 vs 0.281; 0.158 vs 0.148, P = 0.043) was higher, and FVC decline smaller (-0.073 l/yr vs -0.169 l/yr, P = 0.017). The benefit of pirfenidone on OS and PFS was also seen in patients with probable or possible IPF. CONCLUSIONS: This EMPIRE analysis confirms the favourable outcomes observed for pirfenidone treatment in patients with definitive IPF and indicates benefits also for patients with probable or possible IPF.


Subject(s)
Idiopathic Pulmonary Fibrosis , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Humans , Idiopathic Pulmonary Fibrosis/diagnosis , Lung , Probability , Pyridones/pharmacology , Retrospective Studies , Treatment Outcome , Vital Capacity
2.
Front Med (Lausanne) ; 8: 729203, 2021.
Article in English | MEDLINE | ID: mdl-35004713

ABSTRACT

Idiopathic pulmonary fibrosis (IPF) is a rare lung disease with poor prognosis. The diagnosis and treatment possibilities are dependent on the health systems of countries. Hence, comparison among countries is difficult due to data heterogeneity. Our aim was to analyse patients with IPF in Central and Eastern Europe using the uniform data from the European Multipartner IPF registry (EMPIRE), which at the time of analysis involved 10 countries. Newly diagnosed IPF patients (N = 2,492, between March 6, 2012 and May 12, 2020) from Czech Republic (N = 971, 39.0%), Turkey (N = 505, 20.3%), Poland (N = 285, 11.4%), Hungary (N = 216, 8.7%), Slovakia (N = 149, 6.0%), Israel (N = 120, 4.8%), Serbia (N = 95, 3.8%), Croatia (N = 87, 3.5%), Austria (N = 55, 2.2%), and Bulgaria (N = 9, 0.4%) were included, and Macedonia, while a member of the registry, was excluded from this analysis due to low number of cases (N = 5) at this timepoint. Baseline characteristics, smoking habit, comorbidities, lung function values, CO diffusion capacity, high-resolution CT (HRCT) pattern, and treatment data were analysed. Patients were significantly older in Austria than in the Czech Republic, Turkey, Hungary, Slovakia, Israel, and Serbia. Ever smokers were most common in Croatia (84.1%) and least frequent in Serbia (39.2%) and Slovakia (42.6%). The baseline forced vital capacity (FVC) was >80% in 44.6% of the patients, between 50 and 80% in 49.3%, and <50% in 6.1%. Most IPF patients with FVC >80% were registered in Poland (63%), while the least in Israel (25%). A typical usual interstitial pneumonia (UIP) pattern was present in 67.6% of all patients, ranging from 43.5% (Austria) to 77.2% (Poland). The majority of patients received antifibrotic therapy (64.5%); 37.4% used pirfenidone (range 7.4-39.8% between countries); and 34.9% nintedanib (range 12.6-56.0% between countries) treatment. In 6.8% of the cases, a therapy switch was initiated between the 2 antifibrotic agents. Significant differences in IPF patient characteristics and access to antifibrotic therapies exist in EMPIRE countries, which needs further investigation and strategies to improve and harmonize patient care and therapy availability in this region.

3.
Respir Res ; 21(1): 11, 2020 Jan 08.
Article in English | MEDLINE | ID: mdl-31915023

ABSTRACT

BACKGROUND: Several registries of idiopathic pulmonary fibrosis (IPF) have been established to better understand its natural history, though their size and duration of follow-up are limited. Here, we describe the large European MultiPartner IPF Registry (EMPIRE) and validate predictors of long-term survival in IPF. METHODS: The multinational prospective EMPIRE registry enrolled IPF patients from 48 sites in 10 Central and Eastern European countries since 2014. Survival from IPF diagnosis until death was estimated, accounting for left-truncation. The Cox proportional hazards regression model was used to estimate adjusted hazard ratios (HR) of death for prognostic factors, using restricted cubic splines to fit continuous factors. RESULTS: The cohort included 1620 patients (mean age at diagnosis 67.6 years, 71% male, 63% smoking history), including 75% enrolled within 6 months of diagnosis. Median survival was 4.5 years, with 45% surviving 5 years post-diagnosis. Compared with GAP stage I, mortality was higher with GAP stages II (HR 2.9; 95% CI: 2.3-3.7) and III (HR 4.0; 95% CI: 2.8-5.7) while, with redefined cut-offs, the corresponding HRs were 2.7 (95% CI: 1.8-4.0) and 5.8 (95% CI: 4.0-8.3) respectively. Mortality was higher with concurrent pulmonary hypertension (HR 2.0; 95% CI: 1.5-2.9) and lung cancer (HR 2.6; 95% CI: 1.3-4.9). CONCLUSIONS: EMPIRE, one of the largest long-term registries of patients with IPF, provides a more accurate confirmation of prognostic factors and co-morbidities on longer term five-year mortality. It also suggests that some fine-tuning of the indices for mortality may provide a more accurate long-term prognostic profile for these patients.


Subject(s)
Idiopathic Pulmonary Fibrosis/epidemiology , Registries , Aged , Comorbidity , Europe/epidemiology , Female , Follow-Up Studies , Humans , Male , Prospective Studies , Reproducibility of Results , Survival Rate/trends , Time Factors
5.
Respir Med ; 135: 57-61, 2018 02.
Article in English | MEDLINE | ID: mdl-29414454

ABSTRACT

BACKGROUND: The assessment of the clinical symptoms is the weakest link of the pulmonary embolism (PE) diagnostic algorithm. Despite the presence of highly sensitive and specific imaging methods, verifying PE remains difficult due to nonspecific clinical symptoms and frequently its subclinical course. OBJECTIVE: The aim of this study is to improve the recognition of PE by investigating the clinical presentation and short-term prognosis of unprovoked PE in comparison to provoked PE. The study was directed to patients who suffer from PE as a primary disease. METHODS: This prospective observational study included 331 patients with PE, approved by computer tomographic pulmoangiography. They were categorized as having unprovoked or provoked PE, according to their epidemiological data. The clinical characteristics and one-month mortality rate were compared between both groups. RESULTS: About 67% of the patients had provoking factors and ∼33% had unprovoked PE. The patients in the unprovoked PE-group were younger compared to provoked PE-group (56.67 ±â€¯17.95 vs 63.76 ±â€¯14.58, p < .0001) and the males predominated vs females (62.04% vs 37.96%, p = .012). The patients with unprovoked PE had more previous thromboembolic events compared to provoked PE-group (30.56% vs 19.45%, p = .022) and a larger thrombotic burden (p = .001). Dyspnea (85.18% vs 85.13%), chest pain (47.22% vs 46.85%), cough (43.92% vs 45.94%), hemoptysis (16.67% vs 14.41%), hemodynamic instability (9.26% vs 8.56%), deep venous thrombosis (49.51% vs 44.5%) had similar frequencies in both groups. No significant differences in the means of systolic pressure of arteria pulmonalis, D-dimer, arterial blood gases, Revised Geneva probability score were found. One-month mortality was lower in unprovoked PE-group than in provoked (1.85% vs 8.52%, p = .042). CONCLUSIONS: Unprovoked PE occurs at a younger age, more frequently in males. It is characterized by the following significant variables: higher Wells score, lower PESI score, lower CRP, higher thrombotic burden and lower one-month mortality rate, compared to provoked PE.


Subject(s)
Computed Tomography Angiography/methods , Lung/diagnostic imaging , Pulmonary Embolism/diagnostic imaging , Venous Thromboembolism/epidemiology , Adult , Aged , Algorithms , Bulgaria/epidemiology , Cost of Illness , Female , Hemodynamics/physiology , Humans , Lung/blood supply , Male , Middle Aged , Mortality/trends , Prognosis , Prospective Studies , Pulmonary Embolism/diagnosis , Pulmonary Embolism/epidemiology , Pulmonary Embolism/mortality , Risk Factors , Venous Thromboembolism/complications
6.
Folia Med (Plovdiv) ; 58(1): 64-6, 2016 03 01.
Article in English | MEDLINE | ID: mdl-27383881

ABSTRACT

Prothrombin 20210 G>A mutation is the second most frequent inherited factor increasing the risk for developing venous thromboembolism (VTE). The risk for VTE in homozygous carriers of this mutation is not well studied because of their rarity are rare. We report a case of a homozygous carrier of prothrombin mutation: a young man with massive pulmonary embolism, and his family - an asymptomatic homozygous sister, heterozygous parents with asymptomatic mother, and father with history of deep venous thrombosis (DVT). To our knowledge, this is the first reported case of homozygous prothrombin mutation carriers in Bulgaria and the other Balkan countries. We conclude that the homozygous prothrombin mutation creates predisposition for VTE that can manifest or not depending on additional factors, one of which could be male gender.


Subject(s)
Heterozygote , Homozygote , Prothrombin/genetics , Pulmonary Embolism/genetics , Venous Thrombosis/genetics , Adult , Fathers , Female , Genetic Predisposition to Disease , Humans , Male , Middle Aged , Mothers , Mutation , Pulmonary Embolism/diagnostic imaging , Sex Factors , Siblings , Tomography, X-Ray Computed , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...